

TAKAFULINK DANA ESG GLOBAL

All information as at 30 September 2023 unless otherwise stated


Semua maklumat adalah seperti pada 30 September 2023 melainkan jika dinyatakan

Objective / Objektif Dana

Takafulink Dana ESG Global (The Fund) aims to maximise returns over long term by investing in a qualified Sustainable and Responsible Investment (SRI) Fund.

Takafulink Dana ESG Global (Dana) bertujuan memaksimumkan pulangan jangka masa panjang dengan melabur dalam Dana Pelaburan Mampan dan Bertanggungjawab (SRI) yang layak.

Where the Fund invests Komposisi Pelaburan Dana



Asset Allocation Peruntukan Aset


	% NAV
1 Nomura Global Shariah Sustainable Equity Fund	95.27
2 Cash, Deposits & Others	4.73

Fund Details / Maklumat Terperinci Dana

Investment Manager / Pengurus Pelaburan	Prudential BSN Takaful Berhad
Inception Date / Tarikh Diterbitkan	20/03/2023
Current Fund Size / Saiz Dana Terkini	RM378,519.65
Annual Fund Management Charge / Caj Pengurusan Dana Tahunan	1.50% per annum
Current NAV / NAB Terkini	RM1.04410

How the Fund has performed / Prestasi Dana

Performance Graph / Jaduan Prestasi Dana
Takafulink Dana ESG Global Vs. Dow Jones Islamic Market Developed Markets Index



Total Price Movement Over the Following Periods / Jumlah Pergerakan Harga Dalam Tempoh Tersebut

	1 month	3 months	6 months	1 year	3 years	5 years	Since Inception
Price Movement / Pergerakan Harga	-4.66%	-4.76%	NA	NA	NA	NA	4.41%
Benchmark / Penanda Aras	-4.05%	-3.79%	NA	NA	NA	NA	8.59%
Outperformance / Perbezaan Prestasi	-0.61%	-0.97%	NA	NA	NA	NA	-4.18%

Source / Sumber: Lipper for Investment Management and Bloomberg, 30 September 2023

TAKAFULINK DANA ESG GLOBAL

All information as at 30 September 2023 unless otherwise stated

Semua maklumat adalah seperti pada 30 September 2023 melainkan jika dinyatakan

Monthly Update / Laporan Bulanan Terkini

Fund Review & Strategy

The Fund returned -4.66% for the month, underperforming the benchmark return of -4.05% by 0.61%. Year-to-date, The Fund returned 4.41%, underperforming the benchmark return of 8.59% by 4.18%. While European Central Bank surprised the market with its interest rate hike announcement, Federal Reserve and Bank of England has paused its rate hike to await for more inflationary signals. Nevertheless, market was digesting the implications of higher rates for longer. As bond yields climbed higher, global equity markets closed lower. The underperformance was attributed to selection in North America mainly due to Industrials and Information Technology sector. No exposure in Energy sector has contributed to the underperformance as crude oil price has continued to surge and attempt to break the \$100 level. The top contributors to performance were AstraZeneca PLC and Gilead. AstraZeneca PLC reported that its TROPION-Breast01 study shows that its key pipeline asset Dato-DXd in metastatic breast cancer has a statistically significant and clinically meaningful improvement for the primary endpoint of progression free survival (PFS). This helps to ease the market concern around the confusion over the outcome of the Tropion-Lung01 trial earlier this year, when the phrase "clinically meaningful" wasn't used. Importantly, a positive trend was also observed on the co-primary endpoint of overall survival (OS). Gilead enjoys a positive read-through from GSK which upgraded 2021-2026 HIV sales CAGR to 6%-8%. Apple Inc was also one of the top contributors with its underweight position. The top detractors were Johnson Control, Thermo Fisher Scientific and Orsted. Johnson Control and Orsted sentiments continue to be sour post its respective earnings and news announcements. The Target Fund Manager thinks that the actions on Johnson Control share price is particular overdone.

Tinjauan dan Strategi Dana

Dana memberikan pulangan -4.66% pada bulan ini, tidak mengatasi pulangan penanda aras -4.05% sebanyak 0.61%. Sejak awal tahun sehingga kini, Dana memperoleh pulangan 4.41%, tidak mengatasi pulangan penanda aras 8.59% sebanyak 4.18%. Walaupun Bank Pusat Eropah mengejutkan pasaran dengan pengumuman kenaikan kadar faedahnya, namun Rizab Persekutuan dan Bank of England sebaliknya menghentikan kenaikan kadar masing-masing kerana menunggu lebih banyak isyarat inflasi. Namun begitu, pasaran mencerna implikasi kadar yang lebih tinggi untuk tempoh lebih lama. Apabila hasil bon meningkat lebih tinggi, pasaran ekuiti global ditutup lebih rendah. Prestasi rendah disebabkan oleh pemilihan di Amerika Utara terutamanya disebabkan sektor Perindustrian dan Teknologi Maklumat. Tiada pendedahan dalam sektor Tenaga menyumbang kepada prestasi hambar kerana harga minyak mentah terus melonjak dan cuba menembusi paras USD100. Penyumbang utama kepada prestasi ialah AstraZeneca PLC dan Gilead. AstraZeneca PLC melaporkan bahawa kajian TROPION-Breast01 menunjukkan bahawa Dato-DXd yang merupakan aset penyumbang utama dalam rawatan kanser payudara metastatik mempunyai penambahbaikan yang signifikan secara statistik dan bermakna secara klinikal ke atas titik akhir utama kemandirian bebas perkembangan (PFS). Ini membantu meredakan kebimbangan kekeliruan pasaran mengenai keputusan percubaan Tropion-Lung01 awal tahun ini, apabila frasa "bermakna secara klinikal" tidak digunakan. Yang penting, trend positif juga diperhatikan pada titik akhir utama bersama kemandirian keseluruhan (OS). Gilead menikmati bacaan positif daripada GSK yang menaik taraf CAGR jualan HIV 2021-2026 kepada 6%-8%. Apple Inc turut menjadi salah satu penyumbang utama kepada prestasi dengan kedudukan kekurangan pegangannya. Penjejas teratas ialah Johnson Control, Thermo Fisher Scientific dan Orsted. Sentimen Johnson Control dan Orsted terus merudum selepas pengumuman pendapatan dan perkembangan masing-masing. Pengurus Dana Sasaran berpendapat bahawa tindakan ke atas harga saham Johnson Control adalah berlebihan.

Source / Sumber: Fund Commentary, September 2023, Nomura Asset Management Malaysia Sdn. Bhd.

Disclaimer

Investments are subject to investment risks including the possible loss of the principal amount invested. The value of the units may fall as well as rise. Past performances of the funds and that of the fund managers are not necessarily indicative of future performance. The price movements indicated are not reflective of the actual return on your investments (which are subject to your premium allocation rate and deduction charges). The actual return on your invested premiums may fluctuate based on the underlying performance of the investment-linked funds. All Takafulink Dana are invested in Shariah-approved securities and/or Islamic private debt securities. This leaflet is for illustrative purposes only. For further details on the terms and conditions, please refer to the policy document. For further details on how you can invest in these funds, please refer to the respective product brochures. In the event of discrepancy between the information in this fact sheet and the policy document, the information in the policy document shall prevail.

Pelaburan adalah tertakluk kepada risiko-risiko pelaburan termasuk kemungkinan kehilangan jumlah wang pokok yang dilabur. Nilai unit mungkin naik ataupun jatuh. Prestasi masa dulu dana-dana atau pengurus-pengurus dana tidak semestinya mencerminkan prestasi masa depan. Pergerakan harga yang ditunjukkan tidak menggambarkan pulangan sebenar pelaburan anda (yang tertakluk kepada kadar peruntukan premium dan caj potongan). Pulangan sebenar ke atas premium yang anda labur mungkin berbeza, bergantung kepada prestasi dana-dana). Semua Takafulink Dana dilaburkan dalam sekuriti yang diluluskan oleh Syariah dan/atau sekuriti hutang swasta Islam. Risalah ini disediakan hanya untuk gambaran semata-mata. Sila rujuk kepada dokumen polisi untuk keterangan lanjut mengenai terma-terma dan syarat-syarat. Untuk keterangan lanjut mengenai bagaimana anda boleh melabur dalam dana-dana ini, sila rujuk kepada risalah-risalah produk yang berkenaan. Jika terdapat perbezaan di antara helaian fakta dan dokumen polisi, maklumat dalam dokumen polisi dianggap muktamad.

PRUDENTIAL BSN

TAKAFUL